Home » Author Archives: Catherine Skari

Author Archives: Catherine Skari

Cypriot Stella Kyriakides named EU Health Commissioner

Cypriot psychologist and politician to take over from Vytenis Andriukaitis on November 1 Stella Kyriakides has got the nod as EU Commissioner for Health, making her part of a strong female presence in the new structure of the next European Commission. Kyriakides, one of 13 women commissioners from 27, replaces ...

Read More »

Delegation visit to Germany – 4-5 July 2019

A TIF delegation visit to Germany took place on 04 – 05 July 2019. The Delegation Team was comprised of Mr George Constantinou (TIF Secretary) and Dr Eva-Maria Knoll (TIF collaborator in Austria and the Maldives). The team was accompanied by Mr. Zabihullah Safai (Board Member of SAM Deutschland e.V. ...

Read More »

FDA Grants Priority Review to Potential Sickle Cell Disease Treatment Voxelotor

  The Food and Drug Administration (FDA) will review an approval application for a drug designed to target the root cause of damage from sickle cell disease (SCD). South San Francisco, California-based Global Blood Therapeutics announced Thursday that the FDA had accepted its application seeking accelerated approval for Voxelotor, an oral drug ...

Read More »

TIF releases new video on thalassaemia prevention

  Thalassaemia is a hereditary blood disease that CAN be prevented! But in what ways? ΤΙF’s latest educational video shines a spotlight on the essential aspect of the disease’s prevention, still challenging  in numerous countries across the world. Our goal? To further improve understanding and knowledge of the prevention’s vital ...

Read More »

Biotech companies issue first joint declaration on human gene editing

Companies involved in human gene editing have entered the ethical debate about the controversial technology, issuing a joint declaration that DNA must not be altered in a way that passes genetic changes on to future generations. The Alliance for Regenerative Medicine (ARM), an international group representing the cell and gene ...

Read More »

Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major pending approval by the EMA

  The Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency’s (EMA) committee responsible for human medicines, has recently adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ”Deferasirox Mylan”, intended for the treatment of chronic iron overload due to blood transfusions in patients with ...

Read More »